$BSX: Trial data disappoints


Sentiment: Negative
Boston Scientific fell about 9% as investors reacted to “underwhelming” clinical-trial information related to its Watchman heart implant (sentimentScore: -0.248). The move shows how single-program readouts can drive sharp repricing even for diversified med-tech leaders.
post-image
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin